Intellia Therapeutics Inc (NTLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Intellia Therapeutics Inc (NTLA) Stock Forecast
Analysts expect Intellia Therapeutics (NTLA) to earn -$3.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $43.32M. Of 20 analysts, 10 rate the stock Buy or Strong Buy, 6 Hold and 4 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 6 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.0% |
| Buy | 9 | 45.0% |
| Hold | 6 | 30.0% |
| Sell | 2 | 10.0% |
| Strong Sell | 2 | 10.0% |
- Consensus
- Hold
- Total analysts
- 20
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 174.7%.
- Fiscal year ending Dec 31, 2026
- -$3.27
- EPS consensus, revenue $43.32M
- Fiscal year ending Dec 31, 2027
- -$2.70
- EPS consensus, revenue $119.01M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.27 | -$3.60 to -$2.71 | 17 | $43.32M | $36.87M to $100.00M | 17 |
| Dec 31, 2027 | -$2.70 | -$3.71 to $0.92 | 17 | $119.01M | $36.76M to $685.60M | 17 |
Quarterly Estimates
The EPS consensus falls from -$0.78 for the quarter ending Dec 31, 2026 to -$0.83 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.78 | -$0.88 to -$0.43 | 19 | $17.38M | $6.86M to $73.08M | 17 |
| Mar 31, 2027 | -$0.83 | -$0.94 to -$0.56 | 8 | $10.84M | $7.00M to $17.00M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 7 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 6 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.27 | -$3.14 | -$3.15 | -$3.16 | -$3.13 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.70 | -$2.56 | -$2.57 | -$2.60 | -$2.56 | N/A |
| Quarter ending Mar 31, 2027 | -$0.83 | -$0.80 | -$0.81 | -$0.85 | -$0.85 | N/A |
Frequently Asked Questions About NTLA
What is the NTLA stock forecast?
Consensus analyst estimates put Intellia Therapeutics's EPS at -$3.27 for the fiscal year ending Dec 31, 2026, on revenue of $43.32M. The consensus rating from 20 analysts is Hold.
How do analysts rate NTLA stock?
Of 20 analysts covering Intellia Therapeutics, 1 rates it Strong Buy, 9 Buy, 6 Hold, 2 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from NTLA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.27, with estimates from -$3.60 to -$2.71 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.70, with estimates from -$3.71 to $0.92 from 17 analysts.
What revenue do analysts expect from Intellia Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $43.32M, with estimates from $36.87M to $100.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $119.01M, with estimates from $36.76M to $685.60M.
How many analysts cover NTLA?
20 analysts rate Intellia Therapeutics stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NTLA pages: Overview, Earnings, Forecast, Financials, Competitors